Top 8 Companies in the Acute Lung Injury Treatment Market

The global acute lung injury treatment market was valued at USD 3.19 billion in 2023, driven by the increasing prevalence of respiratory disorders across the globe. The market is anticipated to grow at a CAGR of 3% during the forecast period of 2024-2032 to achieve a value of USD 4.17 billion by 2032.

Acute lung injury (ALI) is a common condition in which patients suffer from severe respiratory distress and lung inflammation. The incidence and prevalence of ALI are increasing, due to factors like the rising geriatric population, the prevalence of chronic diseases, and increased awareness and diagnosis. Increasing focus on early and accurate diagnosis of acute lung injury is also contributing to the market growth.

The increasing global incidence of acute lung injuries, including acute respiratory distress syndrome (ARDS), and the pressing need for effective treatments are significant drivers of the acute lung injury treatment market. In February 2024, BioAegis Therapeutics, a pioneering biotech company specialising in innovative therapies for inflammatory diseases, announced the commencement of site recruitment for BTI-203, a Phase 2 clinical study of recombinant human gelsolin (rhu-pGSN) for the treatment of ARDS. This study represents a crucial advancement in potential ARDS therapies, as rhu-pGSN offers a novel approach by modulating the immune response to reduce inflammation. The progression of this clinical trial is expected to positively impact the global acute lung injury treatment market growth during the forecast period by potentially introducing a new and effective therapeutic option, stimulating further research and development, and attracting increased investment in this area of critical unmet medical need.

Additionally, growing government funding and investment in research initiatives are propelling advancements in this field. In September 2024, Rice University and Baylor College of Medicine received a grant of USD 2.8 million from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), to conduct research focused on reducing inflammation and lung damage in ARDS patients. This substantial funding highlights a commitment to developing innovative therapies for acute lung injuries. The outcomes of this research are expected to contribute to new treatment modalities, enhancing the effectiveness of available therapies. Consequently, such advancements are poised to drive the growth of the acute lung injury treatment market during the forecast period by addressing unmet medical needs and improving patient outcomes.

Major Companies Shaping the Acute Lung Injury Treatment Market in 2024

1.    Bayer AG

Bayer AG, headquartered in Leverkusen, Germany, is a global life sciences company with core competencies in healthcare and agriculture. In the pharmaceutical sector, Bayer develops and markets innovative medicines. Bayer's respiratory portfolio includes treatments for pulmonary hypertension and other lung diseases. Their commitment to research and development in respiratory health contributes to advancing therapies that may impact conditions like acute lung injury, positioning Bayer as a significant player in the respiratory treatment market.

2.    GSK plc

GSK plc, formerly GlaxoSmithKline, is a British multinational pharmaceutical company, and a leader in respiratory healthcare, with a strong portfolio of medicines addressing asthma and chronic obstructive pulmonary disease (COPD). GSK's expertise in respiratory treatments and ongoing research into inflammatory lung diseases has the potential to contribute to developments in acute lung injury therapies. Their dedication to respiratory health positions them prominently in the global respiratory treatment market.

3.    General Electric

General Electric, founded in 1892 and headquartered in Boston, Massachusetts, United States, is a multinational conglomerate operating in various sectors including healthcare. GE Healthcare provides medical technologies and services, such as advanced imaging equipment, patient monitoring systems, and ventilators, essential in diagnosing and managing acute lung injury. Their innovative solutions in medical imaging and critical care support healthcare providers in treating patients with respiratory conditions, including acute lung injury, making GE a key contributor to the market.

4.    Koninklijke Philips N.V.

Koninklijke Philips N.V., commonly known as Philips, is a Dutch multinational corporation founded in 1891, and headquartered in Amsterdam, Netherlands. Philips focuses on health technology, offering a wide range of products including diagnostic imaging systems, patient monitoring devices, and respiratory care solutions like ventilators. These products are crucial in the management and treatment of acute lung injury. Philips' commitment to improving patient care through innovative technology solidifies its role in the respiratory treatment and critical care equipment market.

5.    Linde plc

Linde plc, headquartered in Guildford, United Kingdom, was formed in 2018 through the merger of Linde AG and Praxair. As a leading global industrial gases and engineering company, Linde supplies medical gases, including oxygen, which is vital in the treatment of acute lung injury. Their healthcare division provides medical gas systems and services to hospitals and care facilities. By ensuring the supply of high-quality medical oxygen and related services, Linde plays a crucial role in supporting the management of respiratory conditions worldwide.

6.    Pfizer Inc.

Pfizer Inc., founded in 1849 and headquartered in New York City, United States, is a global pharmaceutical corporation. Pfizer develops and manufactures medicines and vaccines across various therapeutic areas. While not directly producing treatments specifically for acute lung injury, Pfizer's portfolio includes anti-infectives and anti-inflammatory medications that may be utilised in managing underlying causes or complications associated with acute lung injury. Pfizer's extensive research and development efforts contribute to advancements in therapies that can impact respiratory health.

7.    Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., established in 1901 is the world's largest generic drugs producer. Teva offers a wide range of generic pharmaceuticals, including medications used in treating respiratory conditions. While Teva may not have specific products for acute lung injury, its portfolio includes corticosteroids and bronchodilators that can be used to manage symptoms of various lung diseases. Teva's commitment to providing accessible medications supports the global healthcare system in treating respiratory ailments.

8.    ONY Biotech Inc.

ONY Biotech Inc. specialises in pulmonary surfactant therapy. Founded in 1985, ONY Biotech's primary product is Infasurf® (calfactant), a natural surfactant used to prevent and treat respiratory distress syndrome (RDS) in premature infants. While their focus is neonatal care, surfactant therapy has implications in acute lung injury treatment research. ONY Biotech's expertise in surfactant development positions them as a significant contributor to advancements in respiratory therapies within the biotech sector.